LENZ Therapeutics, Inc. is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. This innovative once-daily eye drop aims to restore near vision, addressing the gradual loss of focusing ability that affects adults typically over age 45, offering a pharmaceutical alternative to reading glasses for a broad patient population. The company is actively commercializing VIZZ™ in the United States while establishing licensing partnerships internationally to expand global access. Headquartered in Solana Beach, California, LENZ Therapeutics operates in the ophthalmic pharmaceuticals sector, supported by a leadership team with deep expertise in biopharmaceutical development, clinical operations, regulatory affairs, manufacturing, marketing, sales, and commercial strategy. Their novel product targets the presbyopia market, providing a targeted solution to improve vision clarity and quality of life for millions impacted by this common age-related condition.